Organon (OGN) Total Non-Current Liabilities (2020 - 2026)
Organon (OGN) recorded quarterly Total Non-Current Liabilities of $11.1 billion in Q1 2026, little changed quarter-over-quarter from $11.1 billion in Q4 2025, and down 4.4% on a YoY basis from $11.6 billion in Q1 2025.
Organon (OGN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $11.1 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.4% year-over-year to $11.1 billion; the TTM figure through Mar 2026 stood at $11.1 billion (down 4.4% YoY), while the FY2025 annual figure was $11.1 billion, down 4.68% from the prior year.
- Total Non-Current Liabilities was $11.1 billion for Q1 2026 at Organon, roughly flat from $11.1 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $11.7 billion in Q4 2023 to a low of $11.1 billion in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $11.4 billion across 5 years, with a median of $11.4 billion in 2022.
- Biggest YoY gain for Total Non-Current Liabilities was 270.75% in 2022; the steepest drop was 11.13% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $11.4 billion in 2022, then grew by 2.45% to $11.7 billion in 2023, then retreated by 0.55% to $11.7 billion in 2024, then fell by 4.68% to $11.1 billion in 2025, then climbed by 0.02% to $11.1 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $11.1 billion (Q1 2026), $11.1 billion (Q4 2025), and $11.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 11.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.11 Bn |
| Dec 31, 2025 | 11.11 Bn |
| Sep 30, 2025 | 11.52 Bn |
| Jun 30, 2025 | 11.65 Bn |
| Mar 31, 2025 | 11.62 Bn |
| Dec 31, 2024 | 11.65 Bn |
| Sep 30, 2024 | 11.59 Bn |
| Jun 30, 2024 | 11.46 Bn |
| Mar 31, 2024 | 11.29 Bn |
| Dec 31, 2023 | 11.72 Bn |
| Sep 30, 2023 | 11.18 Bn |
| Jun 30, 2023 | 11.14 Bn |
| Mar 31, 2023 | 11.08 Bn |
| Dec 31, 2022 | 11.44 Bn |
| Sep 30, 2022 | 11.06 Bn |
| Jun 30, 2022 | 11.30 Bn |
| Mar 31, 2022 | 11.39 Bn |
| Dec 31, 2021 | 11.73 Bn |
| Sep 30, 2021 | 12.45 Bn |
| Jun 30, 2021 | 12.36 Bn |